相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Dassault Systèmes signed a definitive agreement to acquire AI-native drug-safety firm ArisGlobal for approximately $1.8 billion in cash plus up to $200 million in contingent AI revenue milestones. - ArisGlobal's LifeSphere platform serves over 200 customers including half of the top 50 global biopharma companies and processes more than 12 million patient safety reports annually. - The acquisition creates a unified data and intelligence platform connecting discovery, clinical trials, manufacturing, and regulated operations across the full therapy lifecycle. - The transaction is expected to close in the second half of 2026, subject to regulatory approvals, and is projected to be accretive to revenue growth and EPS in Year 1.
- Caidya and Simbec-Orion have completed a strategic combination, creating a differentiated global CRO supporting biopharma innovators from First-in-Human through registration. - The combined organization brings together dMed, Clinipace and Simbec-Orion, with deep regional roots in Asia, the United States and Europe, including substantial clinical trial experience in China. - Caidya plans to deepen expertise in oncology, hematology, rare and orphan diseases, cell and gene therapy, CNS and cardio-metabolic interventions over a five-year horizon. - The company is integrating AI-powered insights through partners such as Medidata and biotx.ai to support earlier decisions on indications, biomarkers, endpoints and patient selection.
- The clinical trial software market surpassed $900 million in 2024 and is projected to exceed $1 billion in 2025, with the SaaS segment growing at a 17.14% CAGR. - SaaS platforms are democratizing access to clinical trial infrastructure, enabling mid-size biotechs, academic medical centers, and community sites to leverage tools once reserved for large pharma. - FDA's October 2024 updated guidance on electronic systems raises compliance stakes, making vendor qualification under 21 CFR Part 11 a critical regulatory function rather than a procurement checkbox. - WCG's ClinSphere platform exemplifies the competitive shift toward integration depth across site operations and training, targeting mid-market sponsors that enterprise platforms treat as secondary buyers.
- A series of cyberattacks on medtech sponsors, including Boston Scientific and Medtronic, has exposed how sponsor-hosted eClinical infrastructure failures can disrupt active clinical trials mid-study. - When sponsor IT systems go down, sites lose simultaneous access to EDC, IRT/RTSM, eISF, and monitoring dashboards, creating a source documentation crisis and a cascade of protocol deviations. - ICH E6(R3) Section 5.5 and FDA guidance place the contingency-planning burden on sponsors, yet most site SOPs lack a pre-authorized decision tree for initiating backup protocols during an outage. - Sites and sponsors need cyberattack-specific contingency plans, including pre-authorized backup procedures and communication channels independent of the sponsor's compromised IT environment.
- Industry executives from Thermo Fisher Scientific and Medidata identify structural barriers and lack of early STEM education access as primary drivers of women's underrepresentation in life sciences. - Female leaders emphasize that diverse research teams are essential for advancing precision medicine, with women's health research particularly suffering from historical male-centered approaches. - Companies are implementing mentorship programs and flexible work arrangements to retain women throughout their careers, addressing mid-career dropout rates that affect industry talent pipelines.
- Medidata and The Menarini Group have expanded their 14-year partnership to deploy AI Study Build technology, reducing clinical trial startup time from months to weeks. - Stemline Therapeutics, Menarini's oncology subsidiary, will leverage AI-driven workflows to independently build and launch oncology studies using data from over 38,000 trials. - The partnership aims to accelerate the delivery of transformational cancer treatments to patients by modernizing the trial lifecycle from protocol to patient enrollment. - Stemline has already achieved the milestone of launching its first oncology study entirely in-house using the Medidata Data Experience platform.
- Medidata and CRIO have launched a strategic partnership creating a "plug-and-play" digital pipeline that automates clinical data transfer from eSource systems directly into the Medidata Platform across over 2,500 research sites in approximately 30 countries. - The integration achieves near 100% data accuracy through automated source-to-EDC transfer and reduces data entry time by 90%, with one in four US research sites engaged in chronic condition trials now leveraging this ecosystem. - The collaboration eliminates manual data bridging between systems, dramatically reducing queries and data changes while accelerating workflows for clinical sites that were previously overlooked by traditional integration models.
- A Medidata-commissioned survey reveals that 56% of organizations are actively using AI in clinical trials or implementing it, with 73% of users reporting the technology has met or exceeded expectations. - Clinical trial complexity has increased significantly, with nearly half (45%) of new drug development time spent on "white space" - unproductive periods between trial activities that have lengthened cycle times by seven months since 2020. - Agentic AI systems are emerging as powerful solutions to automate routine tasks across the trial lifecycle, from protocol design and data review to informed consent authoring and trial master file management. - AI implementation is delivering tangible benefits including 70% improved data accuracy, 61% streamlined data collection, and enhanced capabilities in protocol optimization, patient identification, and regulatory compliance activities.
- Sanofi and Medidata announced an expansion of their 10-plus-year collaboration to leverage AI-embedded platform solutions across clinical workflows. - The partnership will utilize Medidata's Patient, Data, and Study Experiences to streamline operations, enhance data quality, and reduce costs and delays in clinical trials. - Sanofi will employ Medidata's decentralized clinical trial expertise along with strategic consulting and end-to-end operational support to expedite therapy development. - The collaboration aims to unify fragmented trial processes, diminish silos, and ultimately speed new therapies to market with improved patient outcomes.
- Medidata has expanded its six-year partnership with the NHMRC Clinical Trials Centre at the University of Sydney, now supporting 30 concurrent studies through its unified platform. - The collaboration enables streamlined clinical trial operations by consolidating multiple data systems, improving data management capabilities and research efficiency. - The CTC utilizes Medidata solutions particularly for studies that may contribute to regulatory submissions, with emphasis on adaptive and platform trial development. - The partnership demonstrates Medidata's proactive approach to global data privacy and security compliance while supporting complex and evolving trial settings.
